International Stem Cell (ISCO) Accumulated Expenses (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Accumulated Expenses of $428000.0 for Q4 2025, down 18.79% year-over-year from $527000.0 in Q4 2024, and down 5.31% quarter-over-quarter from $452000.0 in Q3 2025.
International Stem Cell (ISCO) Accumulated Expenses (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Accumulated Expenses for 16 consecutive years, with $428000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Accumulated Expenses fell 18.79% year-over-year to $428000.0; the TTM figure through Dec 2025 stood at $428000.0 (down 18.79% YoY), while the FY2025 annual figure was $428000.0, down 18.79% from the prior year.
- Accumulated Expenses eased to $428000.0 in Q4 2025 per ISCO's latest filing, from $452000.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $651000.0 in Q2 2025 and bottomed at $284000.0 in Q3 2021.
- Historically, Accumulated Expenses has averaged $506450.0 across 5 years, with a median of $506500.0 in 2022.
- Annual changes were most pronounced in 2021 — Accumulated Expenses slipped 24.06% — and 2022, when it surged 67.25%.
- International Stem Cell's Accumulated Expenses stood at $404000.0 in 2021, then advanced by 25.74% to $508000.0 in 2022, then fell by 4.53% to $485000.0 in 2023, then increased by 8.66% to $527000.0 in 2024, then retreated by 18.79% to $428000.0 in 2025.
- Business Quant data shows ISCO's Accumulated Expenses at $428000.0 in Q4 2025, $452000.0 in Q3 2025, and $651000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | International Stem Cell | 3.76 Mn | 2.67 Mn | 1.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 969,000.00 |
| Dec 31, 2025 | 428,000.00 |
| Sep 30, 2025 | 452,000.00 |
| Jun 30, 2025 | 651,000.00 |
| Mar 31, 2025 | 608,000.00 |
| Dec 31, 2024 | 527,000.00 |
| Sep 30, 2024 | 475,000.00 |
| Jun 30, 2024 | 572,000.00 |
| Mar 31, 2024 | 578,000.00 |
| Dec 31, 2023 | 485,000.00 |
| Sep 30, 2023 | 442,000.00 |
| Jun 30, 2023 | 521,000.00 |
| Mar 31, 2023 | 632,000.00 |
| Dec 31, 2022 | 508,000.00 |
| Sep 30, 2022 | 475,000.00 |
| Jun 30, 2022 | 501,000.00 |
| Mar 31, 2022 | 505,000.00 |
| Dec 31, 2021 | 404,000.00 |
| Sep 30, 2021 | 284,000.00 |
| Jun 30, 2021 | 521,000.00 |